<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Nucl Med Mol Imaging</journal-id>
      <journal-id journal-id-type="iso-abbrev">Eur. J. Nucl. Med. Mol. Imaging</journal-id>
      <journal-title-group>
        <journal-title>European Journal of Nuclear Medicine and Molecular Imaging</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1619-7070</issn>
      <issn pub-type="epub">1619-7089</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27342416</article-id>
      <article-id pub-id-type="pmc">4969351</article-id>
      <article-id pub-id-type="publisher-id">3447</article-id>
      <article-id pub-id-type="doi">10.1007/s00259-016-3447-9</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Image of the Month</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><sup>18</sup>F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Giesel</surname>
            <given-names>Frederik L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cardinale</surname>
            <given-names>Jens</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sch&#xE4;fer</surname>
            <given-names>Martin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neels</surname>
            <given-names>Oliver</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bene&#x161;ov&#xE1;</surname>
            <given-names>Martina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mier</surname>
            <given-names>Walter</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haberkorn</surname>
            <given-names>Uwe</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kopka</surname>
            <given-names>Klaus</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1334-8260</contrib-id>
          <name>
            <surname>Kratochwil</surname>
            <given-names>Clemens</given-names>
          </name>
          <address>
            <phone>+49-6221-56-7732</phone>
            <email>clemens.kratochwil@med.uni-heidelberg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department for Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120 Heidelberg, Germany </aff>
        <aff id="Aff2"><label>2</label>Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>25</day>
        <month>6</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2016</year>
      </pub-date>
      <volume>43</volume>
      <fpage>1929</fpage>
      <lpage>1930</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>14</day>
          <month>6</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag Berlin Heidelberg 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>
      <graphic position="anchor" xlink:href="259_2016_3447_Figa_HTML" id="MO1"/>
    </p>
    <p>The biochemical and radiological responses to radionuclide therapy with <sup>177</sup>Lu-PSMA-617 targeting prostate-specific membrane antigen (PSMA) make it a promising approach to the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) [<xref ref-type="bibr" rid="CR1">1</xref>]. However, PSMA-617 has been reported to have slower tumour accumulation and clearance kinetics than PSMA-11, and the latter is still therefore the preferred diagnostic agent when labelled with generator-produced <sup>68</sup>Ga which has a short half-life (68&#xA0;min) [<xref ref-type="bibr" rid="CR2">2</xref>]. A PSMA-targeting <sup>18</sup>F-labelled PET tracer could be produced with higher activity in a cyclotron and the half-life (110&#xA0;min) would allow both late imaging beyond 1&#xA0;h after injection and shipping to satellite institutions. However, the structure of the currently most-used <sup>18</sup>F-labelled PSMA tracer, <sup>18</sup>F-DCFPyl, is different from that of PSMA-617, and like PSMA-11 it might be a suboptimal surrogate for stratifying patients according to their suitability for therapy with <sup>177</sup>Lu-PSMA-617 [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
    <p>Based on the scaffold of PSMA-617, the novel compound <sup>18</sup>F-PSMA-1007 was developed. As shown in the image (<bold>a</bold>, <bold>d</bold>), PSMA-1007 shares the Glu-urea-Lys motif targeting the catalytic domain of PSMA and the naphthalene-based linker region considered to cotarget the hydrophobic accessory pocket [<xref ref-type="bibr" rid="CR4">4</xref>], while in the radiolabel-bearing moiety glutamic acids were added to mimic the carboxylic acid groups of the DOTA chelator to retain the polar charge influencing clearance kinetics.</p>
    <p>The image also shows a patient with mCRPC who was staged using <sup>18</sup>F-PSMA-1007 (<bold>b</bold> PET 1&#xA0;h after injection, maximum intensity projection) and treatment with <sup>177</sup>Lu-PSMA-617 (<bold>c</bold> planar scan 24&#xA0;h after injection, geometric mean). In analogy to the chemical structure, the uptake in tumour and normal organs is very similar with the two compounds.</p>
    <p>Thus, <sup>18</sup>F-PSMA-1007 and <sup>177</sup>Lu-PSMA-617 seem to be a perfect theragnostic tandem. Due to the preferred physical characteristics of <sup>18</sup>F for PET imaging and the possibility for large-scale production in a cyclotron, <sup>18</sup>F-PSMA-1007 is also a promising alternative to <sup>68</sup>Ga-PSMA-11 for diagnostic purposes. However, non-inferior diagnostic accuracy has still to be proven in a larger cohort.</p>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
<sup>18</sup>F-PSMA-1007 is the subject of a patent application (EP 15 002 800.9, DKFZ)</p>
      </fn>
    </fn-group>
    <notes notes-type="conflict-interest">
      <title>Compliance with ethical standards</title>
      <sec id="FPar2">
        <title>Ethical approval</title>
        <p>As this is a retrospective case report of a patient in regular clinical care but not a clinical trial, ethical approval was not needed.</p>
      </sec>
      <sec id="FPar3">
        <title>Informed consent</title>
        <p>Written informed consent for imaging with an experimental tracer and publication of the individual patient history was obtained.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kratochwil</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giesel</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Stefanova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bene&#x161;ov&#xE1;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bronzel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Afshar-Oromieh</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617</article-title>
          <source>J Nucl Med</source>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Afshar-Oromieh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hetzheim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kratochwil</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benesova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Neels</surname>
              <given-names>OC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions</article-title>
          <source>J Nucl Med</source>
          <year>2015</year>
          <volume>56</volume>
          <issue>11</issue>
          <fpage>1697</fpage>
          <lpage>1705</lpage>
          <pub-id pub-id-type="doi">10.2967/jnumed.115.161299</pub-id>
          <pub-id pub-id-type="pmid">26294298</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szabo</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Mena</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Plyku</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nidal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Eisenberger</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer</article-title>
          <source>Mol Imaging Biol</source>
          <year>2015</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>565</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="doi">10.1007/s11307-015-0850-8</pub-id>
          <pub-id pub-id-type="pmid">25896814</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barinka</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Byun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dusich</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Banerjee</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Castanares</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization</article-title>
          <source>J Med Chem</source>
          <year>2008</year>
          <volume>51</volume>
          <fpage>7737</fpage>
          <lpage>7743</lpage>
          <pub-id pub-id-type="doi">10.1021/jm800765e</pub-id>
          <pub-id pub-id-type="pmid">19053759</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
